Donor lymphocyte infusions (DLIs) induce effective graft-versus-tumor responses in patients with multiple myeloma who relapse after allogeneic hematopoietic stem-cell transplantation. cell-surface BCMA may contribute directly to tumor rejection in vivo. Introduction Allogeneic Alisertib hematopoietic stem-cell transplantation (HSCT) has been shown to be an effective therapy for patients with multiple myeloma.1,2 In part, the efficacy of… Continue reading Donor lymphocyte infusions (DLIs) induce effective graft-versus-tumor responses in patients with